-
Something wrong with this record ?
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
K. Bolsewig, EAJ. Willemse, P. Sánchez-Juan, A. Rábano, M. Martínez, JD. Doecke, G. Bellomo, L. Vermunt, D. Alcolea, S. Halbgebauer, S. In 't Veld, N. Mattsson-Carlgren, K. Veverova, CJ. Fowler, L. Boonkamp, M. Koel-Simmelink, Z. Hussainali, DN....
Language English Country England, Great Britain
Document type Journal Article, Multicenter Study
Grant support
R21 AG056974
NIA NIH HHS - United States
RF1 AG056850
NIA NIH HHS - United States
RF1 AG061566
NIA NIH HHS - United States
860197
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
NLK
Directory of Open Access Journals
from 2015
Free Medical Journals
from 2010
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2019-01-01
Open Access Digital Library
from 2015-01-01
Open Access Digital Library
from 2015-01-01
Medline Complete (EBSCOhost)
from 2012-11-01
Health & Medicine (ProQuest)
from 2019-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
Springer Nature OA/Free Journals
from 2010-12-01
Springer Nature - nature.com Journals - Fully Open Access
from 2010-12-01
- MeSH
- Biomarkers * blood cerebrospinal fluid MeSH
- Lewy Body Disease * drug therapy blood cerebrospinal fluid MeSH
- Dopa Decarboxylase * metabolism MeSH
- Dopamine Agents therapeutic use MeSH
- Cohort Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Parkinson Disease * drug therapy blood cerebrospinal fluid MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
Alzheimer's Centre Reina Sofia CIEN Foundation ISCIII Madrid Spain
Amsterdam Neuroscience Neurodegeneration program Amsterdam UMC Amsterdam The Netherlands
Australian E Health Research Centre CSIRO Herston QLD Australia
Barcelonaβeta Brain Research Center Pasqual Maragall Foundation Barcelona Spain
Clinical Memory Research Unit Lund University Lund Sweden
Department of Clinical Research University Hospital Basel University of Basel Basel Switzerland
Department of Neurology Alzheimer Center Amsterdam Amsterdam UMC Amsterdam The Netherlands
Department of Neurology University Hospital and University of Basel Basel Switzerland
Department of Neurology University Hospital Ulm Ulm Germany
Florey Institute The University of Melbourne Melbourne VIC Australia
German Center for Neurodegenerative Diseases Ulm Germany
Hospital del Mar Research Institute Barcelona Spain
Neurology Clinic Skåne University Hospital Lund Sweden
Wallenberg Center for Molecular Medicine Lund University Lund Sweden
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010165
- 003
- CZ-PrNML
- 005
- 20250429135348.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41467-025-56293-z $2 doi
- 035 __
- $a (PubMed)39881147
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bolsewig, Katharina $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands. k.bolsewig@amsterdamumc.nl $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands. k.bolsewig@amsterdamumc.nl $1 https://orcid.org/0000000331167789
- 245 10
- $a Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment / $c K. Bolsewig, EAJ. Willemse, P. Sánchez-Juan, A. Rábano, M. Martínez, JD. Doecke, G. Bellomo, L. Vermunt, D. Alcolea, S. Halbgebauer, S. In 't Veld, N. Mattsson-Carlgren, K. Veverova, CJ. Fowler, L. Boonkamp, M. Koel-Simmelink, Z. Hussainali, DN. Ruiters, L. Gaetani, A. Toja, J. Fortea, Y. Pijnenburg, AW. Lemstra, WM. van der Flier, J. Hort, M. Otto, O. Hansson, L. Parnetti, CL. Masters, A. Lleó, CE. Teunissen, M. Del Campo Milán
- 520 9_
- $a DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a demence s Lewyho tělísky $x farmakoterapie $x krev $x mozkomíšní mok $7 D020961
- 650 12
- $a DOPA-dekarboxylasa $x metabolismus $7 D004296
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a Parkinsonova nemoc $x farmakoterapie $x krev $x mozkomíšní mok $7 D010300
- 650 12
- $a biologické markery $x krev $x mozkomíšní mok $7 D015415
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dopaminové látky $x terapeutické užití $7 D015259
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a longitudinální studie $7 D008137
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Willemse, Eline A J $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Department of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland $u Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland $u Department of Neurology, University Hospital and University of Basel, Basel, Switzerland
- 700 1_
- $a Sánchez-Juan, Pascual $u Centro de Investigación Biomédica en Red en enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain $u Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain
- 700 1_
- $a Rábano, Alberto $u Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain $1 https://orcid.org/0000000193206566
- 700 1_
- $a Martínez, Minerva $u Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain $1 https://orcid.org/0000000290362595
- 700 1_
- $a Doecke, James D $u Australian E-Health Research Centre, CSIRO, Herston, QLD, Australia $1 https://orcid.org/0000000328630293
- 700 1_
- $a Bellomo, Giovanni $u Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy $1 https://orcid.org/0000000304565650
- 700 1_
- $a Vermunt, Lisa $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands $u Department of Neurology, Alzheimer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands $1 https://orcid.org/0000000174206384
- 700 1_
- $a Alcolea, Daniel $u Centro de Investigación Biomédica en Red en enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain $u Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain $1 https://orcid.org/0000000238193245
- 700 1_
- $a Halbgebauer, Steffen $u Department of Neurology, University Hospital Ulm, Ulm, Germany $u German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany $1 https://orcid.org/0000000287115702
- 700 1_
- $a In 't Veld, Sjors $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a Mattsson-Carlgren, Niklas $u Clinical Memory Research Unit, Lund University, Lund, Sweden $u Neurology Clinic, Skåne University Hospital, Lund, Sweden $u Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
- 700 1_
- $a Veverova, Katerina $u Memory Clinic, Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000258451854
- 700 1_
- $a Fowler, Christopher J $u Florey Institute, The University of Melbourne, Melbourne, VIC, Australia
- 700 1_
- $a Boonkamp, Lynn $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a Koel-Simmelink, Marleen $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a Hussainali, Zulaiga $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a Ruiters, Daimy N $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a Gaetani, Lorenzo $u Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy $1 https://orcid.org/0000000339678954
- 700 1_
- $a Toja, Andrea $u Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy $1 https://orcid.org/0009000095007632
- 700 1_
- $a Fortea, Juan $u Centro de Investigación Biomédica en Red en enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain $u Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain $1 https://orcid.org/000000021340638X
- 700 1_
- $a Pijnenburg, Yolande $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands $u Department of Neurology, Alzheimer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a Lemstra, Afina W $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands $u Department of Neurology, Alzheimer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a van der Flier, Wiesje M $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands $u Department of Neurology, Alzheimer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands $u Department of Epidemiology & Biostatistics, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands $1 https://orcid.org/0000000187666224
- 700 1_
- $a Hort, Jakub $u Memory Clinic, Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Otto, Markus $u Department of Neurology, University Hospital Ulm, Ulm, Germany $1 https://orcid.org/0000000342734267
- 700 1_
- $a Hansson, Oskar $u Clinical Memory Research Unit, Lund University, Lund, Sweden $1 https://orcid.org/0000000184677286
- 700 1_
- $a Parnetti, Lucilla $u Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy $1 https://orcid.org/0000000157223967
- 700 1_
- $a Masters, Colin L $u Florey Institute, The University of Melbourne, Melbourne, VIC, Australia
- 700 1_
- $a Lleó, Alberto $u Centro de Investigación Biomédica en Red en enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain $u Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain $1 https://orcid.org/0000000225685478
- 700 1_
- $a Teunissen, Charlotte E $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Amsterdam Neuroscience, Neurodegeneration program, Amsterdam UMC, Amsterdam, The Netherlands $1 https://orcid.org/0000000240610837
- 700 1_
- $a Del Campo Milán, Marta $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, The Netherlands $u Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain $u Hospital del Mar Research Institute (IMIM), Barcelona, Spain $1 https://orcid.org/0000000328083699
- 773 0_
- $w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 16, č. 1 (2025), s. 1139
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39881147 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135343 $b ABA008
- 999 __
- $a ok $b bmc $g 2311508 $s 1247246
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 16 $c 1 $d 1139 $e 20250129 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
- GRA __
- $a R21 AG056974 $p NIA NIH HHS $2 United States
- GRA __
- $a RF1 AG056850 $p NIA NIH HHS $2 United States
- GRA __
- $a RF1 AG061566 $p NIA NIH HHS $2 United States
- GRA __
- $a 860197 $p EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
- LZP __
- $a Pubmed-20250415
